Cancer News and Research

Latest Cancer News and Research

Idera Pharmaceuticals presents TLR antagonist preclinical hyperlipidemia data at Keystone Symposia conference

Idera Pharmaceuticals, Inc. presented data on the evaluation of a Toll-like receptor (TLR) antagonist in a preclinical hyperlipidemia model today at the Keystone Symposia conference “Advances in Molecular Mechanisms of Atherosclerosis” being held in Banff, Alberta, Canada. Idera’s proprietary TLR antagonists have dual activity for both TLR7 and TLR9, and present a potentially innovative approach for the treatment of certain autoimmune diseases.

15 Feb 2010

NNDS, SlateXP raise over $75,000 to help children in partnership with UMPS CARE Charities

The National Network of Digital Schools and SlateXP, in partnership with UMPS CARE Charities, are proud to announce that the 5th Annual UMPS CARE Charities Golf Classic has raised over $75,000 for children in need.

15 Feb 2010

Positive interim results from Helix BioPharma's Topical Interferon Alpha-2b Phase II pharmacokinetic study

Helix BioPharma Corp. today announced that the first ten patients that have been enrolled in its Phase II pharmacokinetic study of Topical Interferon Alpha-2b in patients with low-grade cervical lesions have completed the pharmacokinetic primary endpoint analyses with positive findings.

14 Feb 2010

Debiopharm receives AFSSAPS approval of CTA for Debio 0932 inhibitor, triggers milestone payment to Curis

Curis, Inc., announced today that its licensee Debiopharm S.A. has received approval from France's regulatory authority Agence Française de Securité Sanitaire des Produits de Santé (AFSSAPS) of a Clinical Trial Application (CTA) for small molecule heat shock protein 90 (Hsp90) inhibitor Debio 0932, formerly called CUDC-305. Under the terms of Curis’ and Debiopharm’s August 2009 license agreement, Curis will receive an $8 million milestone payment from Debiopharm for the achievement of this development objective.

12 Feb 2010

"Goin' Bald for Bucks" program: RPCI CEO to shave head and mustache in honor of cancer patients

Dr. Donald L. Trump, President and CEO of Roswell Park Cancer Institute (RPCI), America's first cancer center, will have his head shaved by a Roswell Park cancer patient on March 3, 2010 to honor the Institute's 26,292 patients, and to encourage others to participate in the "Goin' Bald for Bucks" program.

12 Feb 2010

White rye flour bread leads to better insulin and blood sugar levels than wheat bread with rye bran

Wholegrain bread is good and good for you, as most people know. But it is not only the fiber-rich bran, the outer shell of the grain, that is healthful. On the contrary, research at the Lund University Faculty of Engineering shows that bread baked with white rye flour, which is flour made from the inner, white part of the rye kernel, leads to better insulin and blood sugar levels compared with wheat bread with rye bran. White rye flour thus leads to much better values than both regular wheat flour and rye bran. At the same time, much of the bread that is sold in stores today in most countries is in fact baked with wheat flour and bran from various grains.

12 Feb 2010

Viral Genetics: Company update

Our mission is to bring new drug compounds to the marketplace. And we've never been in a stronger position to deliver on that promise. We've built the solid foundation needed to take drug therapies from the laboratory to the marketplace. After years in development, we believe several of our most promising compounds are moving closer to clinical trials.

12 Feb 2010

Histone modifications associated with pancreatic cancer development and progression

Specific chemical modifications to proteins called histones, which are found in the nucleus of cells and act as spools around which DNA is wound, can be used to predict prognosis and response to treatment in subsets patients with pancreatic cancer, a study by researchers at UCLA's Jonsson Comprehensive Cancer Center has found.

12 Feb 2010

Gold nanoparticles for cancer treatment

World Gold Council (WGC) has today published 'Gold for Good: Gold and nanotechnology in the age of innovation', a research paper detailing new scientific and technological innovations using gold. The report, which was produced in conjunction with Cientifica Ltd, the world's leading source of global business and investor intelligence about nanotechnologies, demonstrates how gold nanoparticles offer the potential to overcome many of the serious issues facing mankind over the coming decades.

12 Feb 2010

New project to unravel secret lives of cancer cells may help produce new cancer therapies

A team of scientists from Princeton University and The Cancer Institute of New Jersey has embarked on a major new project to unravel the secret lives of cancer cells that go dormant and self-cannibalize to survive periods of stress. The work may help produce new cancer therapies to stem changes that render cancer cells dangerous and resistant to treatment.

12 Feb 2010

PAN to provide co-payment assistance for medications to underinsured patients through five new funds

Patient Access Network Foundation will expand its services to provide co-payment assistance for medications to underinsured patients through five new funds -- including grants of up to $10,000 per year for prostate cancer patients.

12 Feb 2010

Cal-EPA intents to add BPA to state's list of chemicals known to cause cancer

The California Environmental Protection Agency signaled intent to add bisphenol A (BPA) to the state's list of chemicals known to cause cancer or birth defects, adding to evidence the chemical should be banned from food and beverage containers.

12 Feb 2010

Peregrine Pharmaceuticals' Cotara specifically targets solid tumors and anti-tumor activity

Peregrine Pharmaceuticals, Inc. (PPHM) today reported publication of data in the online edition of the journal Current Cancer Therapy Reviews that supports the clinical potential of the company's novel brain cancer agent Cotara® for the treatment of patients with glioblastoma multiforme (GBM), the deadliest form of brain cancer. Cotara specifically targets cells at the center of brain tumors, so its radioactive payload is able to kill cancer cells while leaving healthy tissue largely unaffected. Cotara is currently being tested in a Phase II clinical trial in recurrent GBM patients.

12 Feb 2010

IPF added to Social Security's "Compassionate Allowances" program

The Coalition for Pulmonary Fibrosis is praising Social Security Commissioner Michael Astrue's announcement this morning via press release that Idiopathic Pulmonary Fibrosis (IPF), also known as Pulmonary Fibrosis (PF), and a listing of 37 other diseases and life-threatening medical conditions are the latest additions to Social Security's "Compassionate Allowances" program.

12 Feb 2010

MITA endorses eight key principles to reduce unnecessary radiation exposure and medical errors

The Medical Imaging & Technology Alliance (MITA), the leading association representing the manufacturers, innovators and developers of medical imaging and radiation therapy systems, today endorsed eight key principles to reduce exposure to unnecessary medical radiation, further minimize medical errors and improve reporting of adverse events.

12 Feb 2010

Study shows benefits of stent grafts over balloon angioplasty for patients who undergo dialysis

A randomized multicenter study of 190 patients at 13 medical centers shows-- for the first time-- the "superior" benefit of stent grafts over balloon angioplasty for maintaining function of dialysis access grafts in kidney failure patients who undergo dialysis. Until now, no other therapy has proven more effective than angioplasty.

12 Feb 2010

Third party reexamination of Phase III study of Ereska meets primary endpoint

Javelin Pharmaceuticals, Inc. today announced that a reexamination conducted by a third party of pain score measurements from its Phase III study of Ereska™ (intranasal ketamine) showed that top line results for its primary endpoint were statistically significant. Previously, Javelin had reported that the top line results for its primary endpoint were not statistically significant.

12 Feb 2010

United Airlines to deliver teddy bears to kids undergoing cancer treatment across the country

Starting today, United Airlines employees will begin delivering thousands of teddy bears to kids undergoing cancer treatment at hospitals across the country through a partnership with the American Cancer Society® that raised almost 27 million Mileage Plus miles.

12 Feb 2010

Antibodies also contribute to severe dengue virus-induced disease, confirms La Jolla Institute for Allergy & Immunology

A leading immunology research institute has validated the long-held and controversial hypothesis that antibodies - usually the "good guys" in the body's fight against viruses - instead contribute to severe dengue virus-induced disease, the La Jolla Institute for Allergy & Immunology announced today. The finding has major implications for the development of a first-ever vaccine against dengue virus, a growing public health threat which annually infects 50 to 100 million people worldwide, causing a half million cases of the severest form.

12 Feb 2010

Genzyme announces 2-year data from eliglustat tartrate Phase 2 trial for Gaucher disease

Genzyme Corporation announced today two-year follow-up data from patients enrolled in the phase 2 clinical trial for its investigational oral therapy for Gaucher disease type 1 known as eliglustat tartrate (formerly Genz-112638). Continued improvements were observed across all endpoints, including bone disease, at the two-year timepoint, compared with baseline. The two-year results were presented for the first time today at the Lysosomal Disease Network WORLD Symposium in Miami, Fla.

12 Feb 2010

Cancer News and Research

Latest Cancer News and Research

Idera Pharmaceuticals presents TLR antagonist preclinical hyperlipidemia data at Keystone Symposia conference

NNDS, SlateXP raise over $75,000 to help children in partnership with UMPS CARE Charities

Positive interim results from Helix BioPharma's Topical Interferon Alpha-2b Phase II pharmacokinetic study

Debiopharm receives AFSSAPS approval of CTA for Debio 0932 inhibitor, triggers milestone payment to Curis

"Goin' Bald for Bucks" program: RPCI CEO to shave head and mustache in honor of cancer patients

White rye flour bread leads to better insulin and blood sugar levels than wheat bread with rye bran

Viral Genetics: Company update

Histone modifications associated with pancreatic cancer development and progression

Gold nanoparticles for cancer treatment

New project to unravel secret lives of cancer cells may help produce new cancer therapies

PAN to provide co-payment assistance for medications to underinsured patients through five new funds

Cal-EPA intents to add BPA to state's list of chemicals known to cause cancer

Peregrine Pharmaceuticals' Cotara specifically targets solid tumors and anti-tumor activity

IPF added to Social Security's "Compassionate Allowances" program

MITA endorses eight key principles to reduce unnecessary radiation exposure and medical errors

Study shows benefits of stent grafts over balloon angioplasty for patients who undergo dialysis

Third party reexamination of Phase III study of Ereska meets primary endpoint

United Airlines to deliver teddy bears to kids undergoing cancer treatment across the country

Antibodies also contribute to severe dengue virus-induced disease, confirms La Jolla Institute for Allergy & Immunology

Genzyme announces 2-year data from eliglustat tartrate Phase 2 trial for Gaucher disease

Understanding the DNA Damage Response in Innate Immunity eBook

Advancing Menopause Care: Non-Hormonal Treatments for Vasomotor Symptoms

Building quality into drug development for safer, faster medicines

How Pulp Fixin Is Turning Paper into High-Performance Sustainable Labware

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

Advancing Menopause Care: Non-Hormonal Treatments for Vasomotor Symptoms

Building quality into drug development for safer, faster medicines

How Pulp Fixin Is Turning Paper into High-Performance Sustainable Labware

Newsletters you may be interested in